HispanicBusiness

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 09/27/12 -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to modulate the immune response, control inflammation, and prevent or treat organ failure, continues to expand market awareness of its CytoSorb® and HemoDefend technologies through exhibits, posters and presentations at a number of key conferences through the end of 2012. These include:

•HAI 2012 (Congress for Anesthesiology and Intensive Care Therapy) - Berlin, Germany - September 13-15, 2012 •ESAO 2012 (European Society for Artificial Organs) - Rostock, Germany - September 26-29, 2012 •AABB & CTTXPO 2012 (American Association of Blood Banks) - Boston, MA - October 6-9, 2012 •ESICM 2012 (European Society of Intensive Care Medicine) - Lisbon, Portugal - October 13-17, 2012 •Brean Murray Caret Life Sciences Summit - New York City, NY - November 7, 2012 •DIVI 2012 (German Interdisciplinary Association for Intensive Care and Emergency Medicine) - Hamburg, Germany - December 5-7, 2012

At ESAO 2012, Dr. Kai Singbartl, MD, MPH will present pre-clinical and clinical data on CytoSorb® in his talk "Cytokine Adsorption in Sepsis" during a symposium on the "Extracorporeal Treatment of Sepsis" chaired by Dr. Patrick Honoré and Dr. Steffen Mitzner. At the University of Pittsburgh, Dr. Singbartl collaborated with Dr. John Kellum on seminal work relating to the effect of CytoSorb® on leukocyte trafficking, inflammation, and organ injury in animal models of sepsis.

At AABB 2012, CytoSorbents was selected for a poster presentation on its HemoDefend technology based upon its abstract "In situ removal of antibodies, free hemoglobin, cytokines and bioactive lipids from pRBCs using hemoadsorbent polymer beads." CytoSorbents will also exhibit its unique "Beads in a Bag" and in-line filter technology for the removal of contaminants that can cause transfusion reactions in transfused blood products.

At the Brean Murray Life Sciences Summit, the company will be among one of more than 30 select public companies to make in-depth group and one-on-one presentations to key institutional investors in the medical device, biotechnology and pharmaceutical sectors.

In addition to this schedule, CytoSorbents will also attend and exhibit at several local and regional conferences in Germany focused on intensive care medicine and extracorporeal therapies.

About Dr. Kai Singbartl

Dr. Kai Singbartl, MD, MPH is Associate Professor of Anesthesiology at Milton S. Hershey Medical Center at Penn State Hershey. Previously, he was Associate Professor of Critical Care Medicine at University of Pittsburgh. Dr. Singbartl's research has focused on the effect of inflammation on organ injury, in particular leukocyte trafficking and acute kidney injury in sepsis. He has also co-developed new urinary biomarkers to predict long-term dialysis dependency. His past research interests include the effects of cryopreservation on red blood cells. His research efforts have been published in leading clinical and scientific journals and he has received a number of awards for his research from international societies. Dr. Singbartl has also presented talks at various national and international meetings, including the Society of Critical Care Medicine (SCCM), the European Society of Intensive Care Medicine (ESICM), American Thoracic Society (ATS), Experimental Biology, and the International Symposium on Intensive Care and Emergency Medicine (ISICEM). He has also been invited to give plenary lectures and chair sessions at leading international meetings, including CHEST and ISICEM.